NEW YORK (GenomeWeb) – Cepheid is collaborating with AstraZeneca, Cubist Pharmaceuticals, and GlaxoSmithKline to develop a rapid diagnostic test that can analyze multi-drug resistant pathogens and help doctors prescribe the most beneficial antibiotics for patients.

Cepheid is currently developing the Xpert Carba-R test for assessing bacteria from rectal swab samples. The goal of the consortium is to enable the test to also analyze a variety of other biological samples, such as respiratory samples from pneumonia patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.